Afimkibart

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Rheumatoid ArthritisAtopic DermatitisCrohn's Disease

181 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

1

Afimkibart

Roche

Phase 3

22

Actos

Takeda

Preclinical

23

Celexa

AbbVie

Preclinical

14

Plaquenil

Jazz Pharmaceuticals

Preclinical

—5

Voltaren

Novartis

Preclinical

—6

Cataflam

Novartis

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

28

Velcade

SShilpa Grover, MD, MPH

Preclinical

29

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

110

Nsaids

Roche

Preclinical

1Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Crohn's Disease4 trials

A Phase 2, Multicenter, Double-blind, Two-arm Study of Subcutaneous RO7790121 for the Treatment of Subjects With Moderate to Severe Active Crohn's Disease

Active, not recruiting·Roche·Phase 2·NCT05910528·21 enrolled

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease

Recruiting·Roche·Phase 3·NCT06819878·600 enrolled

A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2-17 Years With Moderately to Severely Active Crohn's Disease

Recruiting·Roche·Phase 3·NCT07298421·100 enrolled

Show 1 more trial

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease

Recruiting·Roche·Phase 3·NCT06819891·425 enrolled

Moderately to Severely Active Ulcerative Colitis3 trials

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting·Roche·Phase 3·NCT06589986·400 enrolled

A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2 - 17 Years With Moderately to Severely Active Ulcerative Colitis

Recruiting·Roche·Phase 3·NCT07158242·100 enrolled

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting·Roche·Phase 3·NCT06588855·350 enrolled

Rheumatoid Arthritis2 trials

An Extension Study to Evaluate the Long-term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Rheumatoid Arthritis Who Participated in Previous Afimkibart Clinical Trials

Recruiting·Roche·Phase 2·NCT07620392·120 enrolled

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors

Recruiting·Roche·Phase 2·NCT07137598·160 enrolled

Atopic Dermatitis2 trials

An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials

Recruiting·Roche·Phase 2·NCT07223697·120 enrolled

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients With Moderate to Severe Atopic Dermatitis

Active, not recruiting·Roche·Phase 2·NCT06863961·162 enrolled

Ulcerative Colitis1 trial

A Phase I, Multicenter, Open-Label, Single-Agent Study to Assess the Pharmacokinetics of Cytochrome P450 Substrates After Treatment With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting·Roche·Phase 1·NCT07665723·25 enrolled

Details

Drug Info

Related News